Iberdomide plus daratumumab and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (EXCALIBER-RRMM): an open-label, randomised, controlled, phase 3 trial.

Iberdomide combined with daratumumab and dexamethasone increased MRD-negative complete response rates to 41%, nearly doubling the 21% rate with standard therapy in relapsed multiple myeloma.

• Why it matters: Achieving deeper responses like MRD-negativity is crucial for improving long-term outcomes in multiple myeloma, addressing the need for more effective treatments in relapsed or refractory cases.
• What they did: The trial randomized 420 patients across two treatment arms, comparing iberdomide, daratumumab, and dexamethasone versus daratumumab, bortezomib, and dexamethasone, assessing MRD-negative complete response at a median follow-up of 15.7 months.
• The result: The combination including iberdomide significantly improved MRD-negative complete response rates, though it was associated with higher rates of hematologic and infectious adverse events, supporting its potential as an effective treatment option.